Skip to main content

Table 1 Demographic and baseline clinical characteristics

From: Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial

  NVA237 50 μg
(n = 550)
Placebo
(n = 267)
Mean (SD) age, years
[range]
63.8 (9.47)
[40.0-91.0]
64.0 (8.96)
[42.0-85.0]
Male gender, n (%) 454 (82.5) 215 (80.5)
Ethnicity, n (%)   
   Caucasian 346 (62.9) 166 (62.2)
   Asian 195 (35.5) 94 (35.2)
   Black 3 (0.5) 3 (1.1)
   Other 6 (1.1) 4 (1.4)
Mean (SD) body mass index, kg/m2 25.8 (5.88) 25.6 (5.60)
Severity of COPD, n (%)   
   Moderate 331 (60.2) 166 (62.2)
   Severe 217 (39.5) 99 (37.1)
   Very severe 2 (0.4) 2 (0.7)
Mean (SD) duration of COPD, years 5.87 (5.798) 6.49 (6.790)
Baseline COPD exacerbation history*, n (%)   
   0 exacerbations 433 (78.7) 210 (78.7)
   1 exacerbation 90 (16.4) 43 (16.1)
   ≥ 2 exacerbations 27 (4.9) 14 (5.2)
ICS use at baseline, n (%) 301 (54.7) 136 (50.9)
Smoking history, n (%)   
   Ex-smoker 370 (67.3) 176 (65.9)
   Current Smoker 180 (32.7) 91 (34.1)
Mean (SD) duration of smoking, pack years
Mean (SD) FEV1 (L) pre-bronchodilator
Mean (SD) FEV1 (L) post-bronchodilator
44.9 (28.08)
1.34 (0.45)
1.49 (0.46)
44.6 (24.80)
1.28 (0.43)
1.45 (0.45)
Mean (SD) post-bronchodilator FEV1 percentage predicted 54.75 (13.05) 54.33 (12.84)
Mean (SD) post-bronchodilator FEV1 reversibility, (%) 13.0 (14.21) 15.05 (13.70)
Mean (SD) post-bronchodilator FEV1/FVC, (%) 50.15 (10.26) 49.92 (10.22)
  1. *The number of moderate or severe COPD exacerbations in the year prior to screening
  2. SD: standard deviation